State lawmakers are considering regulations for what some call a whole new “breed” of medicine not yet on the U.S. market.

A biosimilar medication is a drug created to mimic another medication without being biologically exact.
The drugs are allowed in Europe, but in the U.S., federal regulators are still drafting rules for the drugs — like which ones will be deemed “interchangeable” with other biologic medicine.